Skip to main content

Advertisement

SpringerLink
Log in

Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Classically, mast cells (MC) are considered as important actors of the innate immune response playing a pivotal role in IgE-mediated allergic and antiparasite responses. In the last two decades, many experimental evidences demonstrated that these hematopoietic-derived cells present in both connective and mucosal tissues are also key modulators of the adaptive immune response and could contribute to autoimmune disease notably in rheumatoid arthritis (RA). Recently, Bader-Meunier et al. reported a series of 31 patients suffering from inflammatory joint diseases associated with mastocytosis, suggesting that mastocytosis was associated with a higher prevalence in spondyloarthritis. We discuss here the possible link between chronic inflammatory arthritis and mastocytosis through the report of a clinical case describing a patient developing RA after a long history of mastocytosis. Of great interest, antihistamine treatment alone was sufficient to treat RA in this patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aletaha D, Neogi T, Silman AJ, et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588. doi:10.1136/ard.2010.138461

    Article  PubMed  Google Scholar 

  2. Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163–172. doi:10.1056/NEJMra1409760

    Article  CAS  PubMed  Google Scholar 

  3. Cruse G, Metcalfe DD, Olivera A (2014) Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin N Am 34:219–237. doi:10.1016/j.iac.2014.01.002

    Article  Google Scholar 

  4. Magliacane D, Parente R, Triggiani M (2014) Current concepts on diagnosis and treatment of mastocytosis. Transl Med UniSa 8:65–74

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Golkar L, Bernhard JD (1997) Mastocytosis. Lancet 349:1379–1385. doi:10.1016/S0140-6736(96)07056-0

    Article  CAS  PubMed  Google Scholar 

  6. DeBruin EJ, Gold M, Lo BC, et al. (2015) Mast cells in human health and disease. Methods Mol Biol 1220:93–119. doi:10.1007/978-1-4939-1568-2_7

    Article  CAS  PubMed  Google Scholar 

  7. Moon TC, St Laurent CD, Morris KE, et al. (2010) Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 3:111–128. doi:10.1038/mi.2009.136

    Article  CAS  PubMed  Google Scholar 

  8. Gurish MF, Boyce JA (2006) Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 117:1285–1291. doi:10.1016/j.jaci.2006.04.017

    Article  CAS  PubMed  Google Scholar 

  9. Kalesnikoff J, Galli SJ (2008) New developments in mast cell biology. Nat Immunol 9:1215–1223. doi:10.1038/ni.f.216

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Urb M, Sheppard DC (2012) The role of mast cells in the defence against pathogens. PLoS Pathog 8:e1002619. doi:10.1371/journal.ppat.1002619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440–452. doi:10.1038/nri2782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18:693–704. doi:10.1038/nm.2755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cruse G, Bradding P (2015) Mast cells in airway diseases and interstitial lung disease. Eur J Pharmacol. doi:10.1016/j.ejphar.2015.04.046

    PubMed  Google Scholar 

  14. Barete S, Assous N, de Gennes C, et al. (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841. doi:10.1136/ard.2009.124511

    Article  CAS  PubMed  Google Scholar 

  15. Biosse-Duplan M, Baroukh B, Dy M, et al. (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174:1426–1434. doi:10.2353/ajpath.2009.080871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rossini M, Zanotti R, Viapiana O, et al. (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127:1127.e1–1127.e4. doi:10.1016/j.amjmed.2014.06.015

    Article  CAS  Google Scholar 

  17. Guillaume N, Desoutter J, Chandesris O, et al. (2013) Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 126:75.e1–75.e7. doi:10.1016/j.amjmed.2012.07.018

    Article  CAS  Google Scholar 

  18. Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124:776–778. doi:10.1016/j.amjmed.2011.02.038

    Article  CAS  PubMed  Google Scholar 

  19. Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36:393–396

    Article  CAS  PubMed  Google Scholar 

  20. Brumsen C, Hamdy NAT, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569. doi:10.1359/jbmr.2002.17.4.567

    Article  PubMed  Google Scholar 

  21. Lim AYN, Ostor AJK, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966. doi:10.1136/ard.2004.029116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(Suppl 6):vi5–vi9. doi:10.1093/rheumatology/kes279

    Article  PubMed  Google Scholar 

  23. Gotis-Graham I, McNeil HP (1997) Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 40:479–489

    Article  CAS  PubMed  Google Scholar 

  24. McNeil HP, Gotis-Graham I (2000) Human mast cell subsets--distinct functions in inflammation? Inflamm Res 49:3–7

    Article  CAS  PubMed  Google Scholar 

  25. Olsson N, Ulfgren AK, Nilsson G (2001) Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann Rheum Dis 60:187–193. doi:10.1136/ard.60.3.187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Buckley MG, Walters C, Wong WM, et al. (1997) Mast cell activation in arthritis: detection of alpha- and beta-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci 93:363–370

    Article  CAS  PubMed  Google Scholar 

  27. Hueber AJ, Asquith DL, Miller AM, et al. (2010) Mast cells express IL-17 A in rheumatoid arthritis synovium. J Immunol 184:3336–3340. doi:10.4049/jimmunol.0903566

    Article  CAS  PubMed  Google Scholar 

  28. Noordenbos T, Yeremenko N, Gofita I, et al. (2012) Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 64:99–109. doi:10.1002/art.33396

    Article  CAS  PubMed  Google Scholar 

  29. Moulin D, Donzé O, Talabot-Ayer D, et al. (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40:216–225. doi:10.1016/j.cyto.2007.09.013

    Article  CAS  PubMed  Google Scholar 

  30. Suurmond J, Rivellese F, Dorjée AL, et al. (2014) Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-205562

    PubMed  Google Scholar 

  31. Suurmond J, van Heemst J, van Heiningen J, et al. (2013) Communication between human mast cells and CD4(+) T cells through antigen-dependent interactions. Eur J Immunol 43:1758–1768. doi:10.1002/eji.201243058

    Article  CAS  PubMed  Google Scholar 

  32. Nakae S, Suto H, Kakurai M, et al. (2005) Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 102:6467–6472. doi:10.1073/pnas.0501912102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Baram D, Vaday GG, Salamon P, et al. (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 167:4008–4016

    Article  CAS  PubMed  Google Scholar 

  34. Suurmond J, van der Velden D, Kuiper J, et al. (2015) Mast cells in rheumatic disease. Eur J Pharmacol. doi:10.1016/j.ejphar.2015.03.085

    PubMed  Google Scholar 

  35. Magarinos NJ, Bryant KJ, Fosang AJ, et al. (2013) Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and −13 zymogens. J Immunol 191:1404–1412. doi:10.4049/jimmunol.1300856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Seitz S, Barvencik F, Koehne T, et al. (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325–2334. doi:10.1007/s00198-013-2305-x

    Article  CAS  PubMed  Google Scholar 

  37. Bader-Meunier B, Livideanu CB, Larroche C, et al. (2014) Association of mastocytosis with inflammatory joint diseases_ a series of 31 patients. Semin Arthritis Rheum 44:362–365. doi:10.1016/j.semarthrit.2014.05.016

    Article  PubMed  Google Scholar 

  38. Eklund KK (2007) Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 217:38–52. doi:10.1111/j.1600-065X.2007.00504.x

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Study design was performed by ICV and DM; study conduct, IL and MK; data collection, ICV and DL; drafting the manuscript, IL, MK, JH, and DM; revising the manuscript content, MK, DL, PN, JYJ, ICV, and DM; approving the final version of the manuscript, IL, MK, JH, DL, PN, JYJ, ICV, and DM; DM and ICV takes responsibility for the integrity of the data analysis.

Author information

Authors and Affiliations

  1. UMR 7365 IMoPA CNRS-Université de Lorraine, Biopôle de l’Université de Lorraine, Campus biologie-santé, 54505, Vandœuvre-lès-Nancy cedex, France

    Ichraq Latar, Meriem Koufany, Julie Hablot, Patrick Netter, Jean-Yves Jouzeau & David Moulin

  2. Department of Rheumatology, Nancy University Hospital, 54511, Vandœuvre-lès-Nancy, France

    Damien Loeuille & Isabelle Chary-Valckenaere

  3. Nancy, University Hospital, CHU de Nancy, Contrat d’interface, Nancy, F-54035, France

    David Moulin

Authors
  1. Ichraq Latar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meriem Koufany
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Hablot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Damien Loeuille
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patrick Netter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Yves Jouzeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isabelle Chary-Valckenaere
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Moulin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Moulin.

Ethics declarations

Disclosures

None.

Additional information

Ichraq Latar and Meriem Koufany contributed equally to this work. Isabelle Chary-Valckenaere and David Moulin contributed equally to this work.

Electronic supplementary material

ESM. 1

(PPTX 434 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Latar, I., Koufany, M., Hablot, J. et al. Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review. Clin Rheumatol 35, 2619–2623 (2016). https://doi.org/10.1007/s10067-016-3368-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3368-9

Keywords

Search

Navigation